Bronchopulmonary Dysplasia
Conditions
Keywords
Bronchopulmonary dysplasia, Microbiome, Microbiota, Premature infant, Observational cohort study
Brief summary
The purpose of this study is to advance our knowledge of the factors that contribute to the development of bronchopulmonary dysplasia (BPD), a chronic lung affecting premature infants. Specifically, the investigators will determine the complexity of the gut microbiota, the genera of the bacteria that naturally live in the gut, and determine if the relative diversity of the gut bacteria is a prognostic indicator of BPD. To accomplish this, the investigators propose to characterize the microbiota of human premature newborns with BPD, then validate this potential mechanism in mice. The investigators will enroll very low birthweight premature infants admitted to the neonatal intensive care units (NICU) at Le Bonheur Children's Hospital and Regional One Health that are at high risk to develop BPD. A cohort of well full term newborns will also be enrolled. Non-invasive stool samples will be obtained weekly over the first month of life. Infants that eventually develop BPD will be paired with infants that did not develop BPD. Stool samples from these infants will be sent for analysis. The investigators expect that reduced complexity of the gut microbiome is associated with BPD. The investigators will model the contribution of reduced microbiome complexity to the risk to develop BPD or death, as well as the association with disease severity. The project investigates important factors leading to the development of BPD, and has the potential to directly translate to therapy for the most significant pulmonary complication of prematurity.
Interventions
DIAGNOSTIC_TEST16S rRNA stool microbiome sequencing.
This is an observational cohort that will undergo gut microbiome sequencing.
Sponsors
University of Tennessee
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Days to 7 Days
Inclusion criteria
1. Newborn humans less than 1 week of age with a birthweight less than 1,500 g, or fetuses with impending delivery and estimated birthweight of less than 1,500 grams. No individuals will be excluded on the basis of sex or ethnicity. 2. Parents can understand and comply with planned study procedures. 3. Parents provide assent/permission prior to any study procedures. Inclusion criteria mothers: 1\. The mother's of infants meeting the infant inclusion criteria above.
Exclusion criteria
1. Diagnosed immunodeficiency disorder. 2. Currently receiving investigational immunomodulatory, probiotic or antiviral agent. 3. Infants whose mothers meet the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Death | from the date of enrollment until the date of death or initial hospital discharge, whichever occurs first, assessed up to up to 3 months | — |
| Bronchopulmonary dysplasia (BPD) | 36 weeks corrected gestational age, until the date of death or initial hospital discharge whichever occurs first, assessed up to up to 3 months | National Institute of Child Health and Disease (NICHD) consensus definition |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Necrotizing Enterocolitis (NEC) | from the date of enrollment until the date of initial hospital discharge or death, whichever occurs first, assessed up to up to 3 months | Modified Bell's staging for NEC \> Stage 2 |
| Maternal Chorioamnionitis | presence on admission | — |
Other
| Measure | Time frame |
|---|---|
| Maternal perinatal antibiotic exposure | from hospital admission until birth of infant |
| Infant antibiotic exposure | birth until 36 weeks corrected gestational age |
Countries
United States
Outcome results
None listed